Peter Boyle

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/598670/publications.pdf

Version: 2024-02-01

394 papers

44,712 citations

100 h-index 200 g-index

400 all docs

400 docs citations

400 times ranked

38330 citing authors

#	Article	IF	CITATIONS
1	Serum polychlorinated biphenyl (PCB) levels and risk of testicular germ cell tumors: A population-based case-control study in Connecticut and Massachusetts. Environmental Pollution, 2021, 273, 116458.	3.7	7
2	The long-term rapid increase in incidence of adenocarcinoma of the kidney in the USA, especially among younger ages. International Journal of Epidemiology, 2019, 48, 1886-1896.	0.9	9
3	Effects of Environmental Exposures on Fetal and Childhood Growth Trajectories. Annals of Global Health, 2018, 82, 41.	0.8	116
4	Changing global policy to deliver safe, equitable, and affordable care for women's cancers. Lancet, The, 2017, 389, 871-880.	6.3	66
5	Letter by Mullie et al Regarding Article, "Estimated Global, Regional, and National Disease Burdens Related to Sugar-Sweetened Beverage Consumption in 2010― Circulation, 2016, 133, e595.	1.6	O
6	Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostateâ€specific antigen (PSA) level: a metaâ€analysis. BJU International, 2016, 118, 731-741.	1.3	104
7	The State of Lung Cancer Research: A Global Analysis. Journal of Thoracic Oncology, 2016, 11, 1040-1050.	0.5	166
8	Physical activity, hormone replacement therapy and breast cancer risk: A meta-analysis of prospective studies. European Journal of Cancer, 2016, 52, 138-154.	1.3	128
9	Relation between Breast Cancer and High Glycemic Index or Glycemic Load: A Meta-analysis of Prospective Cohort Studies. Critical Reviews in Food Science and Nutrition, 2016, 56, 152-159.	5.4	61
10	Observed and Predicted Risk of Breast Cancer Death in Randomized Trials on Breast Cancer Screening. PLoS ONE, 2016, 11, e0154113.	1.1	9
11	MP4-09 ENDOGENOUS AND EXOGENOUS TESTOSTERONE AND THE RISK OF PROSTATE CANCER AND PROSTATE SPECIFIC ANTIGEN. Journal of Urology, 2015, 193, .	0.2	O
12	Screening mammography: Authors' response to Nyström and Tabar and colleagues. Journal of the Royal Society of Medicine, 2015, 108, 431-432.	1.1	1
13	Active and passive smoking and risk of breast cancer: a meta-analysis. Breast Cancer Research and Treatment, 2015, 154, 213-224.	1.1	156
14	Statistical analyses in Swedish randomised trials on mammography screening and in other randomised trials on cancer screening: a systematic review. Journal of the Royal Society of Medicine, 2015, 108, 440-450.	1.1	17
15	Lessons learned from the casualties of war: battlefield medicine and its implication for global trauma care. Journal of the Royal Society of Medicine, 2015, 108, 93-100.	1.1	19
16	Variation of Prostate-specific Antigen Value in Men and Risk of High-grade Prostate Cancer: Analysis of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Study. Urology, 2015, 85, 1117-1122.	0.5	3
17	A birth cohort analysis of the incidence of adenocarcinoma of the uterine cervix in the USA. European Journal of Cancer Prevention, 2015, 24, 240-244.	0.6	6
18	Mouthwash Use and the Prevention of Plaque, Gingivitis and Caries. Oral Diseases, 2014, 20, 1-68.	1.5	19

#	Article	IF	CITATIONS
19	Sweetened carbonated beverage consumption and cancer risk. European Journal of Cancer Prevention, 2014, 23, 481-490.	0.6	34
20	Polymorphisms in DNA repair genes, hair dye use, and the risk of non-Hodgkin lymphoma. Cancer Causes and Control, 2014, 25, 1261-1270.	0.8	17
21	Different time trends by gender for the incidence of Hodgkin's lymphoma among young adults in the USA: a birth cohort phenomenon. Cancer Causes and Control, 2014, 25, 923-931.	0.8	2
22	Pretreatment Levels of Vascular Endothelial Growth Factor in Plasma Predict a Complete Remission Rate and Time to Relapse or Progression in Patients with Diffuse Large B-Cell Lymphoma. Archivum Immunologiae Et Therapiae Experimentalis, 2013, 61, 165-174.	1.0	2
23	Dietary fiber intake and risk of breast cancer by menopausal and estrogen receptor status. European Journal of Nutrition, 2013, 52, 217-223.	1.8	13
24	Reply. BJU International, 2013, 111, E17-8.	1.3	0
25	Reply. BJU International, 2013, 111, E141-2.	1.3	0
26	Serum insulin and C-peptide concentration and breast cancer: a meta-analysis. Cancer Causes and Control, 2013, 24, 873-883.	0.8	40
27	A birth cohort analysis of the incidence of ascending and descending colon cancer in the United States, 1973–2008. Cancer Causes and Control, 2013, 24, 1147-1156.	0.8	8
28	Polymorphisms in patternâ€recognition genes in the innate immunity system and risk of nonâ€Hodgkin lymphoma. Environmental and Molecular Mutagenesis, 2013, 54, 72-77.	0.9	19
29	The benefits and harms of breast cancer screening. Lancet, The, 2013, 381, 800.	6.3	5
30	Polymorphisms in JAK/STAT signaling pathway genes and risk of non-Hodgkin lymphoma. Leukemia Research, 2013, 37, 1120-1124.	0.4	10
31	Blood glucose concentrations and breast cancer risk in women without diabetes: a meta-analysis. European Journal of Nutrition, 2013, 52, 1533-1540.	1.8	33
32	Role of one-carbon metabolizing pathway genes and gene–nutrient interaction in the risk of non-Hodgkin lymphoma. Cancer Causes and Control, 2013, 24, 1875-1884.	0.8	17
33	Epidemiology of head and neck squamous cell carcinoma not related to tobacco or alcohol. Current Opinion in Oncology, 2013, 25, 229-234.	1.1	63
34	Occupational solvent exposure, genetic variation in immune genes, and the risk for non-Hodgkin lymphoma. European Journal of Cancer Prevention, 2013, 22, 77-82.	0.6	7
35	Single-Nucleotide Polymorphisms in Genes Encoding for CC Chemokines were Not Associated with the Risk of Non-Hodgkin Lymphoma. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1332-1335.	1.1	9
36	Polymorphisms in DNA repair pathway genes, body mass index, and risk of nonâ€Hodgkin lymphoma. American Journal of Hematology, 2013, 88, 606-611.	2.0	12

#	Article	IF	CITATIONS
37	Signal stratification of autoantibody levels in serum samples and its application to the early detection of lung cancer. Journal of Thoracic Disease, 2013, 5, 618-25.	0.6	34
38	Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis. BMJ, The, 2012, 345, e4757-e4757.	3.0	527
39	Occupational solvent exposure, genetic variation of DNA repair genes, and the risk of non-Hodgkin's lymphoma. European Journal of Cancer Prevention, 2012, 21, 580-584.	0.6	21
40	Risk of lymphoma in women with breast implants. European Journal of Cancer Prevention, 2012, 21, 274-280.	0.6	30
41	Critical role of prostate biopsy mortality in the number of years of life gained and lost within a prostate cancer screening programme. BJU International, 2012, 110, 1648-1652.	1.3	21
42	EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays. Tumor Biology, 2012, 33, 1319-1326.	0.8	165
43	Genetic Polymorphisms in Oxidative Stress Pathway Genes and Modification of BMI and Risk of Non-Hodgkin Lymphoma: Table 1 Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 866-868.	1.1	8
44	Diabetes and breast cancer risk: a meta-analysis. British Journal of Cancer, 2012, 107, 1608-1617.	2.9	252
45	Dietary Nitrate and Nitrite Intake and Non-Hodgkin Lymphoma Survival. Nutrition and Cancer, 2012, 64, 488-492.	0.9	7
46	Triple-negative breast cancer: epidemiological considerations and recommendations. Annals of Oncology, 2012, 23, vi7-vi12.	0.6	435
47	Genetic polymorphisms in <i>IL10RA</i> and <i>TNF</i> modify the association between blood transfusion and risk of nonâ∈Hodgkin lymphoma. American Journal of Hematology, 2012, 87, 766-769.	2.0	5
48	Changing patterns of bladder cancer in the USA: evidence of heterogeneous disease. BJU International, 2012, 109, 52-56.	1.3	36
49	The IBM Blue Gene/Q Compute Chip. IEEE Micro, 2012, 32, 48-60.	1.8	221
50	Polymorphisms in complement system genes and risk of nonâ€Hodgkin lymphoma. Environmental and Molecular Mutagenesis, 2012, 53, 145-151.	0.9	15
51	Delivering affordable cancer care in high-income countries. Lancet Oncology, The, 2011, 12, 933-980.	5.1	571
52	Polymorphisms in Th1/Th2 Cytokine Genes, Hormone Replacement Therapy, and Risk of Non-Hodgkin Lymphoma. Frontiers in Oncology, 2011, 1, .	1.3	4
53	Cytokine polymorphisms in Th1/Th2 pathway genes, body mass index, and risk of non-Hodgkin lymphoma. Blood, 2011, 117, 585-590.	0.6	37
54	ITFoM – The IT Future of Medicine. Procedia Computer Science, 2011, 7, 26-29.	1.2	17

#	Article	IF	CITATIONS
55	Re. Lehrer S, Green S, Stock RG (2011) Association between number of cell phone contracts and brain tumor incidence in nineteen U.S. States. J Neurooncol 101:505–507. Journal of Neuro-Oncology, 2011, 105, 433-434.	1.4	3
56	Exposure to acrylamide and human cancerâ€"a review and meta-analysis of epidemiologic studies. Annals of Oncology, 2011, 22, 1487-1499.	0.6	79
57	Clinical validation of an autoantibody test for lung cancer. Annals of Oncology, 2011, 22, 383-389.	0.6	185
58	<i>Early</i> CDT-Lung: An Immunobiomarker Test as an Aid to Early Detection of Lung Cancer. Cancer Prevention Research, 2011, 4, 1126-1134.	0.7	128
59	Genetic Variation in Metabolic Genes, Occupational Solvent Exposure, and Risk of Non-Hodgkin Lymphoma. American Journal of Epidemiology, 2011, 173, 404-413.	1.6	30
60	GWAS of Follicular Lymphoma Reveals Allelic Heterogeneity at 6p21.32 and Suggests Shared Genetic Susceptibility with Diffuse Large B-cell Lymphoma. PLoS Genetics, 2011, 7, e1001378.	1.5	93
61	An Estimate of Cancers Attributable to Occupational Exposures in France. Journal of Occupational and Environmental Medicine, 2010, 52, 399-406.	0.9	68
62	Alcohol consumption and non-Hodgkin lymphoma survival. Journal of Cancer Survivorship, 2010, 4, 101-109.	1.5	19
63	Genetic variation in N-acetyltransferases 1 and 2, cigarette smoking, and risk of non-Hodgkin lymphoma. Cancer Causes and Control, 2010, 21, 127-133.	0.8	11
64	Risk of non-Hodgkin lymphoma and nitrate and nitrite from the diet in Connecticut women. Cancer Causes and Control, 2010, 21, 889-896.	0.8	18
65	Light at night and breast cancer risk: results from a population-based case–control study in Connecticut, USA. Cancer Causes and Control, 2010, 21, 2281-2285.	0.8	31
66	Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nature Genetics, 2010, 42, 661-664.	9.4	152
67	Identification of non-Hodgkin's lymphoma prognosis signatures using the CTGDR method. Bioinformatics, 2010, 26, 15-21.	1.8	18
68	Essential considerations in the investigation of associations between insulin and cancer risk using prescription databases. Ecancermedicalscience, 2010, 3, 174.	0.6	0
69	Cancer mortality in Europe, 2000–2004, and an overview of trends since 1975. Annals of Oncology, 2010, 21, 1323-1360.	0.6	340
70	Past Medical History and Pancreatic Cancer Risk: Results From a Multicenter Case-Control Study. Annals of Epidemiology, 2010, 20, 92-98.	0.9	65
71	The globalisation of breast cancer. Breast Cancer Research, 2010, 12, S7.	2.2	37
72	Alcohol poisoning is a main determinant of recent mortality trends in Russia: evidence from a detailed analysis of mortality statistics and autopsies. International Journal of Epidemiology, 2009, 38, 143-153.	0.9	125

#	Article	IF	Citations
73	The causes of cancer in France. Annals of Oncology, 2009, 20, 550-555.	0.6	91
74	Prostate Cancer: Current Evidence Weighs Against Population Screening. Ca-A Cancer Journal for Clinicians, 2009, 59, 220-224.	157.7	47
75	Menstrual and reproductive factors and pancreatic cancer in the SEARCH program of the IARC. Cancer Causes and Control, 2009, 20, 1757-1762.	0.8	17
76	Alcohol consumption and breast cancer risk. Breast Cancer Research, 2009, 11, S3.	2.2	19
77	Declining mortality from bladder cancer in Europe. BJU International, 2008, 101, 11-19.	1.3	80
78	The rs743572 common variant in the promoter of CYP17A1 is not associated with prostate cancer risk or circulating hormonal levels. BJU International, 2008, 101, 492-496.	1.3	12
79	Tobacco smoking and cancer: A metaâ€analysis. International Journal of Cancer, 2008, 122, 155-164.	2.3	720
80	The challenge of cancer control in Africa. Nature Reviews Cancer, 2008, 8, 398-403.	12.8	120
81	The changing pattern of kidney cancer incidence and mortality in Europe. BJU International, 2008, 101, 949-958.	1.3	183
82	Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU International, 2008, 101, 809-816.	1.3	120
83	Do polybrominated diphenyl ethers (PBDE) increase the risk of thyroid cancer?. Bioscience Hypotheses, 2008, 1, 195-199.	0.2	75
84	Curbing the liver cancer epidemic in Africa. Lancet, The, 2008, 371, 367-368.	6.3	44
85	Artificial ultraviolet sources and skin cancers: rationale for restricting access to sunbed use before 18 years of age. Nature Clinical Practice Oncology, 2008, 5, 178-179.	4.3	18
86	Occupational Exposure to Solvents and Risk of Non-Hodgkin Lymphoma in Connecticut Women. American Journal of Epidemiology, 2008, 169, 176-185.	1.6	58
87	Factors influencing attitudes to legislation banning the manufacture and sale of tobacco products. Tobacco Control, 2008, 17, 142-143.	1.8	2
88	Favorable trends in cancer mortality in the European Union but no room for complacency. Annals of Oncology, 2008, 19, 605-606.	0.6	9
89	Need for global action for cancer control. Annals of Oncology, 2008, 19, 1519-1521.	0.6	29
90	Diet, nutrition and cancer: public, media and scientific confusion. Annals of Oncology, 2008, 19, 1665-1667.	0.6	46

#	Article	IF	CITATIONS
91	Epidemiology of lung cancer. , 2008, , 10-19.		O
92	Tamoxifen for the Prevention of Breast Cancer: Late Results of the Italian Randomized Tamoxifen Prevention Trial Among Women With Hysterectomy. Journal of the National Cancer Institute, 2007, 99, 727-737.	3.0	218
93	Ultraviolet Radiation Exposure and Risk of Non-Hodgkin's Lymphoma. American Journal of Epidemiology, 2007, 165, 1255-1264.	1.6	37
94	Nutrients Contributing to One-Carbon Metabolism and Risk of Non-Hodgkin Lymphoma Subtypes. American Journal of Epidemiology, 2007, 167, 287-294.	1.6	22
95	Estimates of the cancer incidence and mortality in Europe in 2006. Annals of Oncology, 2007, 18, 581-592.	0.6	2,332
96	Ala394Thr polymorphism in the clock geneNPAS2: A circadian modifier for the risk of non-Hodgkin's lymphoma. International Journal of Cancer, 2007, 120, 432-435.	2.3	100
97	5α-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia. International Journal of Cancer, 2007, 120, 776-780.	2.3	53
98	The impact of lower urinary tract symptoms and comorbidities on quality of life: the BACH and UREPIK studies. BJU International, 2007, 99, 347-354.	1.3	140
99	International Consortium on Head and Neck Cancer Awareness (ICOHANCA). Oral Oncology, 2007, 43, 841-842.	0.8	7
100	Family history of hematopoietic and non-hematopoietic malignancies and risk of non-Hodgkin lymphoma. Cancer Causes and Control, 2007, 18, 351-359.	0.8	6
101	Genetic polymorphisms in the oxidative stress pathway and susceptibility to non-Hodgkin lymphoma. Human Genetics, 2007, 121, 161-168.	1.8	65
102	Tobacco: deadly in any form or disguise. Lancet, The, 2006, 367, 1710-1712.	6.3	29
103	The globalisation of cancer. Lancet, The, 2006, 368, 629-630.	6.3	47
104	Genetic variants in caspase genes and susceptibility to non-Hodgkin lymphoma. Carcinogenesis, 2006, 28, 823-827.	1.3	60
105	Measures of familial aggregation depend on definition of family history: meta-analysis for colorectal cancer. Journal of Clinical Epidemiology, 2006, 59, 114-124.	2.4	89
106	Polymorphisms in DNA repair genes and risk of non-Hodgkin lymphoma among women in Connecticut. Human Genetics, 2006, 119, 659-668.	1.8	81
107	Infant mortality in Central Europe: effects of transition. Gaceta Sanitaria, 2006, 20, 63-66.	0.6	5
108	Estimates of the cancer burden in Europe from radioactive fallout from the Chernobyl accident. International Journal of Cancer, 2006, 119, 1224-1235.	2.3	131

#	Article	IF	Citations
109	The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: A systematic review. International Journal of Cancer, 2006, 120, 1116-1122.	2.3	476
110	Circulating Steroid Hormones and the Risk of Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 86-91.	1.1	159
111	'Environment' in cancer causation and etiological fraction: limitations and ambiguities. Carcinogenesis, 2006, 28, 913-915.	1.3	33
112	Does "Clock" Matter in Prostate Cancer?. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 3-5.	1.1	47
113	Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood, 2006, 107, 4101-4108.	0.6	166
114	Variants in the Prostate-Specific Antigen (PSA) Gene and Prostate Cancer Risk, Survival, and Circulating PSA. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1142-1147.	1.1	24
115	Circulating Insulin-Like Growth Factor-I and Binding Protein-3 and Risk of Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1137-1141.	1.1	59
116	473: Tyrolean Screening Study: Update 2005 - Stage Migration and Decrease of Mortality. Journal of Urology, 2006, 175, 153-154.	0.2	2
117	Tobacco smoking and the British doctors' cohort. British Journal of Cancer, 2005, 92, 419-420.	2.9	6
118	Breast cancer control: Signs of progress, but more work required. Breast, 2005, 14, 429-438.	0.9	43
119	Screening for prostate cancer: updated experience from the tyrol study. Current Prostate Reports, 2005, 3, 5-10.	0.1	12
120	Mortality and survival in breast and colorectal cancer. Nature Clinical Practice Oncology, 2005, 2, 424-425.	4.3	65
121	Preventing the lung cancer epidemic. Annals of Oncology, 2005, 16, 1565-1566.	0.6	20
122	Toward a comprehensive long term nicotine policy. Tobacco Control, 2005, 14, 161-165.	1.8	80
123	A Putative Exonic Splicing Polymorphism in the BCL6 Gene and the Risk of Non-Hodgkin Lymphoma. Journal of the National Cancer Institute, 2005, 97, 1616-1618.	3.0	33
124	Effect of Tamoxifen on Venous Thromboembolic Events in a Breast Cancer Prevention Trial. Circulation, 2005, 111, 650-656.	1.6	138
125	Breast cancer. Lancet, The, 2005, 365, 1727-1741.	6.3	441
126	Transparency in IARC Monographs. Lancet Oncology, The, 2005, 6, 747.	5.1	10

#	Article	IF	CITATIONS
127	Curbing tobacco's toll starts with the professionals: World No Tobacco Day. Lancet, The, 2005, 365, 1990-1992.	6.3	1
128	Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 467-475.	1.1	1,819
129	Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. European Journal of Cancer, 2005, 41, 28-44.	1.3	686
130	Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. European Journal of Cancer, 2005, 41, 45-60.	1.3	1,024
131	Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. European Journal of Cancer, 2005, 41, 2040-2059.	1.3	622
132	Cancer incidence and mortality in Europe, 2004. Annals of Oncology, 2005, 16, 481-488.	0.6	1,046
133	Diet and Nutrient Intakes and Risk of Non-Hodgkin's Lymphoma in Connecticut Women. American Journal of Epidemiology, 2004, 159, 454-466.	1.6	102
134	Trends in cancer mortality in the European Union and accession countries, 1980–2000. Annals of Oncology, 2004, 15, 1425-1431.	0.6	54
135	The case of the disappearing nitrosamines: a potentially global phenomenon. Tobacco Control, 2004, 13, 13-16.	1.8	20
136	Blood Transfusion and Risk of Non-Hodgkin's Lymphoma in Connecticut Women. American Journal of Epidemiology, 2004, 160, 325-330.	1.6	30
137	Serum Polychlorinated Biphenyls, Cytochrome P-450 1A1 Polymorphisms, and Risk of Breast Cancer in Connecticut Women. American Journal of Epidemiology, 2004, 160, 1177-1183.	1.6	85
138	Menstrual and Reproductive Factors and Risk of Non-Hodgkin's Lymphoma among Connecticut Women. American Journal of Epidemiology, 2004, 160, 766-773.	1.6	34
139	Publishing tobacco tar measurements on packets. BMJ: British Medical Journal, 2004, 329, 813-814.	2.4	3
140	Hair-coloring Product Use and Risk of Non-Hodgkin's Lymphoma: A Population-based Case-Control Study in Connecticut. American Journal of Epidemiology, 2004, 159, 148-154.	1.6	98
141	Cancer of the skin: a forgotten problem in Europe. Annals of Oncology, 2004, 15, 5-6.	0.6	56
142	Updated meta-analysis of clinical trials of Serenoa repensextract in the treatment of symptomatic benign prostatic hyperplasia. BJU International, 2004, 93, 751-756.	1.3	121
143	A meta-analysis of trials of transurethral needle ablation for treating symptomatic benign prostatic hyperplasia. BJU International, 2004, 94, 83-88.	1.3	58
144	The prevalence of urinary incontinence in community-dwelling married women: a matter of definition. BJU International, 2004, 94, 1291-1295.	1.3	42

#	Article	IF	CITATIONS
145	Beyond classical meta-analysis: can inadequately reported studies be included?. Drug Discovery Today, 2004, 9, 924-931.	3.2	27
146	Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecologic Oncology, 2004, 95, 593-596.	0.6	222
147	5-Alpha Reductase Inhibition Provides Superior Benefits to Alpha Blockade by Preventing AUR and BPH-Related Surgery. European Urology, 2004, 45, 620-627.	0.9	53
148	Evaluation of the Clinical Benefit of Permixon and Tamsulosin in Severe BPH Patients—PERMAL Study Subset Analysis. European Urology, 2004, 45, 773-780.	0.9	63
149	Foods, nutrients and prostate cancer. Cancer Causes and Control, 2004, 15, 11-20.	0.8	117
150	Prior Medical Conditions and Medication use and Risk of non-Hodgkin lymphoma in Connecticut United States Women. Cancer Causes and Control, 2004, 15, 419-428.	0.8	141
151	Screening for prostate cancer: Updated experience from the Tyrol study. Current Urology Reports, 2004, 5, 220-225.	1.0	15
152	Leveling of prostate cancer mortality in Western Europe. Prostate, 2004, 60, 46-52.	1.2	38
153	Cancer mortality in Europe, 1995-1999, and an overview of trends since 1960. International Journal of Cancer, 2004, 110, 155-169.	2.3	170
154	The update of the Italian Food Composition Database. Journal of Food Composition and Analysis, 2004, 17, 509-522.	1.9	138
155	Testicular cancer: the challenge for cancer control. Lancet Oncology, The, 2004, 5, 56-61.	5.1	30
156	Contribution of three components to individual cancer risk predicting breast cancer risk in Italy. European Journal of Cancer Prevention, 2004, 13, 183-191.	0.6	38
157	Alcohol use and risk of non-Hodgkin's lymphoma among Connecticut women (United States). Cancer Causes and Control, 2003, 14, 687-694.	0.8	43
158	Mammographic breast cancer screening: after the dust has settled. Breast, 2003, 12, 351-356.	0.9	8
159	Lower Urinary Tract Symptoms and Male Sexual Dysfunction: The Multinational Survey of the Aging Male (MSAM-7). European Urology, 2003, 44, 637-649.	0.9	993
160	Early growth, adult body size and prostate cancer risk. International Journal of Cancer, 2003, 103, 241-245.	2.3	74
161	Testicular cancer mortality in Eastern Europe. International Journal of Cancer, 2003, 105, 574-574.	2.3	26
162	Comparison of outcomes in women and men treated with coronary stent implantation. Catheterization and Cardiovascular Interventions, 2003, 58, 20-28.	0.7	23

#	Article	IF	CITATIONS
163	Screening for prostate cancer: have you had your cholesterol measured?. BJU International, 2003, 92, 191-199.	1.3	39
164	Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5î±-reductase inhibitor. BJU International, 2003, 92, 262-266.	1.3	72
165	Sexual factors and prostate cancer. BJU International, 2003, 92, 211-216.	1.3	75
166	The importance of benign urological disease in communities. BJU International, 2003, 92, 342-343.	1.3	1
167	The prevalence of lower urinary tract symptoms in men and women in four centres. The UrEpik study. BJU International, 2003, 92, 409-414.	1.3	249
168	The relationship between lower urinary tract symptoms and health status: the UREPIK study. BJU International, 2003, 92, 575-580.	1.3	54
169	The association between lower urinary tract symptoms and erectile dysfunction in four centres: the UrEpik study. BJU International, 2003, 92, 719-725.	1.3	131
170	Recent trends in mortality from benign prostatic hyperplasia. Prostate, 2003, 56, 207-211.	1.2	10
171	Androgenetic alopecia in men aged 40-69 years: prevalence and risk factors. British Journal of Dermatology, 2003, 149, 1207-1213.	1.4	185
172	Glutathione S-transferase M1 and T1 genetic polymorphisms, alcohol consumption and breast cancer risk. British Journal of Cancer, 2003, 88, 58-62.	2.9	50
173	Cigarette smoking and risk of non-Hodgkin lymphoma subtypes among women. British Journal of Cancer, 2003, 89, 2087-2092.	2.9	46
174	The prevalence of male urinary incontinence in four centres: the UREPIK study. BJU International, 2003, 92, 943-947.	1.3	66
175	European Code Against Cancer and scientific justification: third version (2003). Annals of Oncology, 2003, 14, 973-1005.	0.6	247
176	Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology, 2003, 61, 119-126.	0.5	348
177	Overview of the main outcomes in breast-cancer prevention trials. Lancet, The, 2003, 361, 296-300.	6.3	918
178	Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results. Lancet, The, 2003, 362, 593-597.	6.3	422
179	The future of the nicotine-addiction market. Lancet, The, 2003, 362, 845-846.	6.3	23
180	The epidemiology of prostate cancer. Urologic Clinics of North America, 2003, 30, 209-217.	0.8	109

#	Article	IF	CITATIONS
181	Cancers of the Kidney and Urinary Tract in Patients on Dialysis for End-Stage Renal Disease: Analysis of Data from the United States, Europe, and Australia and New Zealand. Journal of the American Society of Nephrology: JASN, 2003, 14, 197-207.	3.0	269
182	Measuring progress against cancer in Europe: has the 15% decline targeted for 2000 come about?. Annals of Oncology, 2003, 14, 1312-1325.	0.6	110
183	Mortality from major cancer sites in the European Union,1955–1998. Annals of Oncology, 2003, 14, 490-495.	0.6	59
184	ELAC2/HPC2 Polymorphisms, Prostate-Specific Antigen Levels, and Prostate Cancer. Journal of the National Cancer Institute, 2003, 95, 818-824.	3.0	53
185	Cancer mortality in Ireland, 1926–1995. Annals of Oncology, 2003, 14, 323-332.	0.6	6
186	Global summit on mammographic screening. Annals of Oncology, 2003, 14, 1159-1160.	0.6	17
187	Cancer mortality trends in the EU and acceding countries up to 2015. Annals of Oncology, 2003, 14, 1148-1152.	0.6	79
188	Italian Randomized Trial Among Women With Hysterectomy: Tamoxifen and Hormone-Dependent Breast Cancer in High-Risk Women. Journal of the National Cancer Institute, 2003, 95, 160-165.	3.0	141
189	Trends in mortality from Hodgkin's disease in western and eastern Europe. British Journal of Cancer, 2002, 87, 291-293.	2.9	27
190	Regulation of cigarette emissions. Annals of Oncology, 2002, 13, 19-21.	0.6	11
191	Faecal occult blood testing (FOBT) as screening for colorectal cancer: the current controversy. Annals of Oncology, 2002, 13, 16-18.	0.6	9
192	Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology, 2002, 60, 434-441.	0.5	660
193	Tamoxifen for breast cancer among hysterectomised women. Lancet, The, 2002, 359, 1122-1124.	6.3	137
194	Tamoxifen for breast cancer in hysterectomised women. Lancet, The, 2002, 360, 1784-1785.	6.3	2
195	Use of hair colouring products and breast cancer risk. European Journal of Cancer, 2002, 38, 1647-1652.	1.3	28
196	An Estimate of Prostate Cancer Prevalence in Italy. Tumori, 2002, 88, 367-369.	0.6	4
197	Comparison of a Phytotherapeutic Agent (Permixon) with an \hat{l} ±-Blocker (Tamsulosin) in the Treatment of Benign Prostatic Hyperplasia: A 1-Year Randomized International Study. European Urology, 2002, 41, 497-507.	0.9	147
198	Relation of childhood brain tumors to exposure of parents and children to tobacco smoke: The Search international case-control study. International Journal of Cancer, 2002, 100, 206-213.	2.3	48

#	Article	IF	Citations
199	Epidemiology of colorectal cancer. British Medical Bulletin, 2002, 64, 1-25.	2.7	282
200	Cigarette smoking, glutathione-s-transferase M1 and t1 genetic polymorphisms, and breast cancer risk (United States). Cancer Causes and Control, 2002, 13 , $637-645$.	0.8	33
201	A case-control study of lung cancer among Czech women. Lung Cancer, 2001, 31, 111-122.	0.9	32
202	The anti-smoking climate in EU countries and Poland. Lung Cancer, 2001, 32, 1-5.	0.9	42
203	Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology, 2001, 58, 417-424.	0.5	280
204	Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. Urology, 2001, 58, 717-722.	0.5	53
205	Guidelines for the diagnosis and treatment of benign prostatic hyperplasia: a comparative, international overview. Urology, 2001, 58, 642-650.	0.5	124
206	Western and eastern European trends in testicular cancer mortality. Lancet, The, 2001, 357, 1853-1854.	6.3	48
207	Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet, The, 2001, 358, 861-865.	6.3	625
208	Epidemiology of Prostate Cancer. European Urology, 2001, 39, 2-3.	0.9	10
209	Smoking and prostate cancer: Findings from an Australian case-control study. Annals of Oncology, 2001, 12, 761-765.	0.6	37
210	Changed trends of cancer mortality in the elderly. Annals of Oncology, 2001, 12, 1467-1477.	0.6	59
211	Dietary glycemic load and colorectal cancer risk. Annals of Oncology, 2001, 12, 173-178.	0.6	188
212	Lactation and breast cancer risk: a case–control study in Connecticut. British Journal of Cancer, 2001, 84, 1472-1476.	2.9	54
213	Preoperative hormone therapy trials for breast cancer. Breast, 2001, 10, 1-5.	0.9	5
214	The association between induced and spontaneous abortion and risk of breast cancer in Slovenian women aged 25–54. Breast, 2001, 10, 291-298.	0.9	3
215	Epidemiology of osteoporosis. Journal of Epidemiology and Biostatistics, 2001, 6, 185-192.	0.4	17
216	The regulation of tobacco and tobacco smoke. Annals of Oncology, 2000, 11, 909-914.	0.6	11

#	Article	IF	Citations
217	Response More About: Sunscreen Use and Duration of Sun Exposure: a Double-Blind, Randomized Trial. Journal of the National Cancer Institute, 2000, 92, 1532-1533.	3.0	6
218	Joint effects of nine polychlorinated biphenyl (PCB) congeners on breast cancer risk. International Journal of Epidemiology, 2000, 29, 975-982.	0.9	63
219	Exposure to Electromagnetic Fields from Use of Electric Blankets and Other In-Home Electrical Appliances and Breast Cancer Risk. American Journal of Epidemiology, 2000, 151, 1103-1111.	1.6	38
220	Breast cancer incidence rates in Slovenia 1971–1993. International Journal of Epidemiology, 2000, 29, 969-974.	0.9	7
221	Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: Results from an international comparative study. American Journal of Kidney Diseases, 2000, 35, 157-165.	2.1	242
222	Meta-analysis of studies on breast cancer risk and diet. European Journal of Cancer, 2000, 36, 636-646.	1.3	338
223	Meta-analysis of clinical trials of Permixon in the treatment of symptomatic benign prostatic hyperplasia. Urology, 2000, 55, 533-539.	0.5	111
224	Update on cancer control in women. International Journal of Gynecology and Obstetrics, 2000, 70, 263-303.	1.0	43
225	ABC of colorectal cancer: Epidemiology. BMJ: British Medical Journal, 2000, 321, 805-808.	2.4	405
226	Breast Cancer Risk Associated with Congeners of Polychlorinated Biphenyls. American Journal of Epidemiology, 2000, 152, 50-58.	1.6	92
227	Meta-Analysis of Published Clinical Trials of a Ribosomal Vaccine (Ribomunyl?? *) in Prevention of Respiratory Infections. BioDrugs, 2000, 14, 389-408.	2.2	21
228	The rise and fall of prostate cancer. European Journal of Cancer Prevention, 2000, 9, 381-385.	0.6	16
229	Epidemiology of Prostate Cancer Chemoprevention. European Urology, 1999, 35, 370-376.	0.9	25
230	Energy intake and dietary pattern in cancer of the oral cavity and pharynx. Cancer Causes and Control, 1999, 10, 439-444.	0.8	32
231	Larynx cancer in Slovakia and the role of anatomical subsites. Oral Oncology, 1999, 35, 564-570.	0.8	9
232	?-Benzene hexachloride in breast adipose tissue and risk of breast carcinoma. , 1999, 85, 2212-2218.		20
233	Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland. , 1999 , 40 , $105-114$.		26
234	Population density and childhood leukaemia: results of the EUROCLUS study. European Journal of Cancer, 1999, 35, 439-444.	1.3	42

#	Article	IF	Citations
235	Cancer mortality in Europe, 1990–1994, and an overview of trends from 1955 to 1994. European Journal of Cancer, 1999, 35, 1477-1516.	1.3	139
236	Age-Period-Cohort Models. Journal of Clinical Epidemiology, 1999, 52, 569-583.	2.4	141
237	Regulation of carcinogens in cigarettes. Lancet, The, 1999, 354, 1036.	6.3	3
238	Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study. Lancet, The, 1999, 353, 2111-2115.	6.3	224
239	Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet, The, 1999, 354, 93-99.	6.3	773
240	Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. Urology, 1999, 54, 662-669.	0.5	204
241	Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology, 1999, 53, 581-589.	0.5	327
242	Cancer screening in otorhinolaryngology. Oral Oncology, 1998, 34, 1-4.	0.8	5
243	Breast cancer risk and nutrient intake among French Canadians in Montreal: a case-control study. Breast, 1998, 7, 108-113.	0.9	11
244	Age at any birth and breast cancer risk. , 1998, 17, 431-445.		2
245	Age-period-cohort analysis of chronic disease rates. I: modelling approach. , 1998, 17, 1305-1323.		136
246	Age-period-cohort models of chronic disease rates. II: graphical approaches., 1998, 17, 1325-1340.		30
247	Double-blind, placebo-controlled trial to assess the efficacy and tolerability of mepartricin in the treatment of BPH., 1998, 37, 246-252.		15
248	Open debate on hormone-replacement therapy. Lancet, The, 1998, 352, 836.	6.3	8
249	Tar concentrations in cigarettes and carcinogen content. Lancet, The, 1998, 352, 787-788.	6.3	17
250	Sorting the hype from the facts in melanoma. Lancet, The, 1998, 352, 738-739.	6.3	3
251	Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Lancet, The, 1998, 352, 93-97.	6.3	624
252	Cancer mortality in Europe: effects of age, cohort of birth and period of death. European Journal of Cancer, 1998, 34, 118-141.	1.3	109

#	Article	IF	Citations
253	Mortality after the Treatment of Hyperthyroidism with Radioactive Iodine. New England Journal of Medicine, 1998, 338, 712-718.	13.9	263
254	Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology, 1998, 51, 428-436.	0.5	206
255	Biologic Activity of Tamoxifen at Low Doses in Healthy Women. Journal of the National Cancer Institute, 1998, 90, 1461-1467.	3.0	98
256	Population Attributable Risk for Breast Cancer: Diet, Nutrition, and Physical Exercise. Journal of the National Cancer Institute, 1998, 90, 389-394.	3.0	183
257	Genetic polymorphism of N-acetyltransferases, glutathione S-transferase M1 and NAD(P)H:quinone oxidoreductase in relation to malignant and benign pancreatic disease risk. European Journal of Cancer Prevention, 1998, 7, 215-223.	0.6	69
258	Prostate specific antigen (PSA) testing as screening for prostate cancer: The current controversy. Annals of Oncology, 1998, 9, 1263-1264.	0.6	24
259	Colorectal cancer screening: Health policy or a continuing research issue?. Annals of Oncology, 1998, 9, 581-584.	0.6	4
260	Epidemiology of Sociodemographic Characteristics, Lifestyle, Medical History, and Colon Cancer: A Case-Control Study among French Canadians in Montreal. Cancer Detection and Prevention, 1998, 22, 396-404.	2.1	39
261	Sociodemographic Characteristics, Smoking, Medical and Family History, and Breast Cancer. Cancer Detection and Prevention, 1998, 22, 485-494.	2.1	25
262	Pancreatitis and the Risk of Pancreatic Cancer. Pancreas, 1997, 14, 106-107.	0.5	1
263	Should subjects who used psoralen suntan activators be screened for melanoma?. Annals of Oncology, 1997, 8, 435-437.	0.6	16
264	Cancer, cigarette smoking and premature death in Europe: a review including the Recommendations of European Cancer Experts Consensus Meeting, Helsinki, October 1996. Lung Cancer, 1997, 17, 1-60.	0.9	166
265	Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology, 1997, 49, 839-845.	0.5	143
266	Attacks on tobacco industry. Lancet, The, 1997, 350, 890.	6.3	0
267	Time trend of female breast carcinoma In Situ by race and histology in Connecticut, U.S.A European Journal of Cancer, 1997, 33, 96-100.	1.3	18
268	Decline in mortality from testicular cancer in West Germany after reunification. Lancet, The, 1997, 350, 744.	6.3	29
269	Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52â€^705 women with breast cancer and 108â€^411 women without breast cancer. Lancet, The, 1997, 350, 1047-1059.	6.3	2,328
270	Global burden of cancer. Lancet, The, 1997, 349, S23-S26.	6.3	53

#	Article	IF	Citations
271	European Cancer Experts recommendations for tobacco control. Annals of Oncology, 1997, 8, 9-13.	0.6	6
272	Risk of tongue cancer associated with tobacco smoking and alcohol consumption: a case-control study. Oral Oncology, 1997, 33, 82-85.	0.8	32
273	Oral leukoplakias: to treat or not?. Oral Oncology, 1997, 33, 317-321.	0.8	43
274	The increase of Hodgkin's disease incidence among young adults. , 1997, 79, 2209-2218.		34
275	Nutritional factors and colon carcinoma. Cancer, 1997, 80, 858-864.	2.0	70
276	Effect of parity and age at delivery on breast cancer risk in Slovenian women aged 25–54 years. , 1997, 73, 1-9.		28
277	Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials. Urology, 1996, 48, 398-405.	0.5	444
278	The relationship between sexual life and urinary condition in the French community. Journal of Clinical Epidemiology, 1996, 49, 1171-1176.	2.4	112
279	Epidemiology of laryngeal cancer. European Journal of Cancer Part B, Oral Oncology, 1996, 32, 293-305.	0.9	133
280	Testicular-cancer incidence and mortality in Slovakia, 1968-90. Lancet, The, 1996, 347, 900-901.	6.3	22
281	Cancer in patients on renal replacement therapy in Lombardy, Italy. Lancet, The, 1996, 347, 59-60.	6.3	15
282	Decrease in Mortality from Benign Prostatic Hyperplasia: a Major Unheralded Health Triumph. Journal of Urology, 1996, 155, 176-180.	0.2	34
283	International Comparison of the Community Prevalence of Symptoms of Prostatism in Four Countries. European Urology, 1996, 29, 15-20.	0.9	89
284	Comparative descriptive epidemiology of oral and oesophageal cancers in Europe. European Journal of Cancer Prevention, 1996, 5, 267-279.	0.6	29
285	Continuing increase in incidence of germ-cell testis cancer in young adults: Experience from Connecticut, USA, 1935–1992. , 1996, 65, 723-729.		91
286	Cancer among patients on renal replacement therapy: A population-based survey in Lombardy, Italy. , 1996, 66, 591-593.		40
287	Cigarette smoking and pancreas cancer: A case-control study of the search programme of the IARC. , 1996, 67, 63-71.		104
288	Time trend and age-period-cohort effect on incidence of thyroid cancer in Connecticut, 1935–1992. , 1996, 67, 504-509.		70

#	Article	IF	Citations
289	Time trend and age-period-cohort effect on incidence of bladder cancer in Connecticut, 1935–1992. , 1996, 68, 172-176.		34
290	The Food Composition Database for an Italian Food Frequency Questionnaire. Journal of Food Composition and Analysis, 1996, 9, 57-71.	1.9	54
291	Nutrition and oral cancer. Cancer Causes and Control, 1996, 7, 101-111.	0.8	79
292	The Continuing Increase in Adenocarcinoma of the Uterine Cervix: A Birth Cohort Phenomenon. International Journal of Epidemiology, 1996, 25, 252-258.	0.9	94
293	Continual importance of descriptive epidemiology in cancer research. Annals of Oncology, 1996, 7, 439-440.	0.6	2
294	Decrease in Mortality from Benign Prostatic Hyperplasia. Journal of Urology, 1996, , 176-180.	0.2	1
295	Pancreatitis and the Risk of Pancreatic Cancer. Pancreas, 1995, 11, 185-189.	0.5	89
296	International patterns in the occurrence of Hodgkin's disease in children and young adult males. International Journal of Cancer, 1995, 61, 165-169.	2.3	67
297	Time trend in pancreatic cancer incidence in connecticut, 1935–1990. International Journal of Cancer, 1995, 61, 622-627.	2.3	18
298	Breast-cancer risk and oral contraceptive use in slovenian women aged 25 to 54. International Journal of Cancer, 1995, 62, 414-420.	2.3	25
299	The Risk of Cancer among Patients with Cystic Fibrosis. New England Journal of Medicine, 1995, 332, 494-499.	13.9	355
300	Patterns of childhood cancer mortality: America, Asia and Oceania. European Journal of Cancer, 1995, 31, 771-782.	1.3	24
301	Alcohol, tobacco, diet and the risk of oral cancer: a pooled analysis of three case-control studies. European Journal of Cancer Part B, Oral Oncology, 1995, 31, 181-187.	0.9	155
302	European school of oncology advisory report to the European Commission for the Europe against cancer programme: Oral carcinogenesis in Europe. European Journal of Cancer Part B, Oral Oncology, 1995, 31, 75-85.	0.9	45
303	Worldwide patterns of prevalence and mortality from benign prostatig hyperplasia. Urology, 1995, 46, 41-46.	0.5	69
304	Geographical and temporal patterns of incidence and mortality from prostate cancer. Urology, 1995, 46, 47-55.	0.5	79
305	Lung cancer and tobacco smoking. Lung Cancer, 1995, 12, 167-181.	0.9	48
306	Impact of Symptoms of Prostatism on Level of Bother and Quality of Life of Men in the French Community. Journal of Urology, 1995, 153, 669-673.	0.2	106

#	Article	IF	Citations
307	Some Statistical Considerations in the Analysis of Case-Control Studies When the Exposure Variables Are Continuous Measurements. Epidemiology, 1994, 5, 164-170.	1.2	48
308	Trends of oral cancer mortality among females worldwide. Cancer Causes and Control, 1994, 5, 255-258.	0.8	27
309	Rising trends of oral cancer mortality among males worldwide: the return of an old public health problem. Cancer Causes and Control, 1994, 5, 259-265.	0.8	134
310	Time trend and the age-period-cohort effect on the incidence of histologic types of lung cancer in connecticut, 1960-1989. Cancer, 1994, 74, 1556-1567.	2.0	102
311	Mothers' active and passive smoking during pregnancy and risk of brain tumours in children. International Journal of Cancer, 1994, 57, 769-774.	2.3	55
312	Dietary fat, olive oil intake and breast cancer risk. International Journal of Cancer, 1994, 58, 774-780.	2.3	285
313	Background, rationale and protocol for a case-control-family study of breast cancer. Breast, 1994, 3, 79-86.	0.9	59
314	Breast cancer detection and oral contraceptive use in Slovenia. Lancet, The, 1994, 343, 1166-1167.	6.3	5
315	Diet in the aetiology of cancer editorial comment. European Journal of Cancer, 1994, 30, 133.	1.3	3
316	Antenatal risk factors for malignant brain tumours in new south wales children. International Journal of Cancer, 1994, 56, 6-10.	2.3	90
317	Perinatal and early postnatal risk factors for malignant brain tumours in New South Wales children. International Journal of Cancer, 1994, 56, 11-15.	2.3	76
318	Trends in cancer mortality in the USSR, 1965–1990. International Journal of Cancer, 1994, 56, 31-39.	2.3	8
319	Epidemiology of Cancer in Women. Medical Science Symposia Series, 1994, , 51-66.	0.0	0
320	The Epidemiology of Oesophageal Cancer in the UK and other European Countries. Journal of the Royal Society of Medicine, 1994, 87, 334-337.	1.1	32
321	The time trend and ageâ€"periodâ€"cohort effects on incidence of adenocarcinoma of the stomach in connecticut from 1955–1989. Cancer, 1993, 72, 330-340.	2.0	76
322	Alcoholic beverage consumption and risk of breast cancer in Spain. Cancer Causes and Control, 1993, 4, 345-353.	0.8	40
323	Epidemiological aspects of lip cancer in Scotland. Community Dentistry and Oral Epidemiology, 1993, 21, 279-282.	0.9	16
324	Cancer incidence and mortality in Europe, 1983–87. International Journal of Public Health, 1993, 38, S155-S229.	2.7	21

#	Article	IF	CITATIONS
325	Pancreatitis and the Risk of Pancreatic Cancer. New England Journal of Medicine, 1993, 328, 1433-1437.	13.9	1,632
326	Trends in cancer mortality in the Americas, 1955–1989. European Journal of Cancer, 1993, 29, 431-470.	1.3	29
327	Development and Validation of a Food Frequency Questionnaire in Spain. International Journal of Epidemiology, 1993, 22, 512-519.	0.9	721
328	Trends in cancer mortality, 1955–1989: Asia, Africa and Oceania. European Journal of Cancer, 1993, 29, 2168-2211.	1.3	25
329	Chemoprevention of oral leukoplakia and chronic esophagitis in an area of high incidence of oral and esophageal cancer. Annals of Epidemiology, 1993, 3, 225-234.	0.9	70
330	A case-control study of oral cancer in Beijing, People's Republic of China. Associations with nutrient intakes, foods and food groups. European Journal of Cancer Part B, Oral Oncology, 1993, 29, 45-55.	0.9	100
331	Ole Møller Jensen memorial EJC travel award. European Journal of Cancer, 1993, 29, 655.	1.3	0
332	Trends in diet-related cancers in Japan: a conundrum?. Lancet, The, 1993, 342, 752.	6.3	36
333	Oral cancer: necessity for prevention strategies. Lancet, The, 1993, 342, 1129.	6.3	34
334	The Hazards of Passive And Active Smoking. New England Journal of Medicine, 1993, 328, 1708-1709.	13.9	42
335	The Hazards of Active and Passive Smoking. New England Journal of Medicine, 1993, 329, 1580-1581.	13.9	2
336	Tea consumption and cancer risk. Nutrition and Cancer, 1992, 17, 27-31.	0.9	138
337	Recent advances in epidemiology of head and neck cancer. Current Opinion in Oncology, 1992, 4, 471-477.	1.1	52
338	Trends of cancer mortality in Europe, 1955–1989: IV, urinary tract, eye, brain and nerves, and thyroid. European Journal of Cancer, 1992, 28, 1210-1281.	1.3	25
339	Trends of cancer mortality in Europe, 1955–1989: V, lymphohaemopoietic and all cancers. European Journal of Cancer, 1992, 28, 1509-1581.	1.3	20
340	Trends in cancer mortality in Europe. European Journal of Cancer, 1992, 28, 7-8.	1.3	5
341	Vitamin A related compounds in the chemoprevention of potentially malignant oral lesions and carcinoma. European Journal of Cancer Part B, Oral Oncology, 1992, 28, 87-89.	0.9	17
342	Trends of cancer mortality in Europe, 1955–1989: III, breast and genital sites. European Journal of Cancer, 1992, 28, 927-998.	1.3	64

#	Article	IF	CITATIONS
343	Trends of cancer mortality in europe, 1955–1989: I, digestive sites. European Journal of Cancer, 1992, 28, 132-235.	1.3	133
344	Patterns of childhood cancer incidence and mortality in Europe. European Journal of Cancer, 1992, 28, 2028-2049.	1.3	33
345	Time trend and age-period-cohort effects on incidence of esophageal cancer in Connecticut, 1935?89. Cancer Causes and Control, 1992, 3, 481-492.	0.8	46
346	A collaborative case-control study of nutrient intake and pancreatic cancer within the search programme. International Journal of Cancer, 1992, 51, 365-372.	2.3	125
347	Risk factors for gallbladder cancer: A polish case-control study. International Journal of Cancer, 1992, 51, 707-711.	2.3	107
348	Epidemiology of non-Hodgkin lymphoma in connecticut 1935-1988. Cancer, 1992, 70, 840-849.	2.0	103
349	Smoking and cancer with emphasis on Europe. European Journal of Cancer & Clinical Oncology, 1991, 27, 94-104.	0.9	55
350	Fats in seasoning and breast cancer risk: an Italian case-control study. European Journal of Cancer & Clinical Oncology, 1991, 27, 420-423.	0.9	16
351	Cancer incidence registration. European Journal of Cancer & Clinical Oncology, 1991, 27, 112-113.	0.9	1
352	Diet and Urine Estrogens among Postmenopausal Women. Oncology, 1991, 48, 490-494.	0.9	46
353	A Case-Control Study of Diet and Cancer of the Pancreas. American Journal of Epidemiology, 1991, 134, 167-179.	1.6	187
354	Analysis of Quantitative Data by Quantiles in Epidemiologic Studies. Epidemiology, 1991, 2, 137-140.	1.2	70
355	Dairy Products and the Risk of Prostatic Cancer. Oncology, 1991, 48, 406-410.	0.9	55
356	Cancer mortality in young adults in Switzerland, 1951–1989. Journal of Cancer Research and Clinical Oncology, 1991, 117, 497-501.	1.2	9
357	Nutritional factors and pancreatic cancer in the francophone community in montréal, Canada. International Journal of Cancer, 1991, 47, 1-6.	2.3	114
358	Pooled analysis of 3 european case-control studies: I. Reproductive factors and risk of epithelial ovarian cancer. International Journal of Cancer, 1991, 49, 50-56.	2.3	154
359	Cancer mortality in the ussr, 1986-88. International Journal of Cancer, 1991, 49, 678-683.	2.3	6
360	Life-time history of smoking and exocrine carcinoma of the pancreas: A population-based case-control study in the Netherlands. International Journal of Cancer, 1991, 49, 816-822.	2.3	57

#	Article	IF	CITATIONS
361	Dietary Indicators of Oral and Pharyngeal Cancer. International Journal of Epidemiology, 1991, 20, 39-44.	0.9	94
362	Risk Factors for Gallstone Disease Requiring Surgery. International Journal of Epidemiology, 1991, 20, 209-215.	0.9	51
363	The application of age, period and cohort models to predict Swiss cancer mortality. Journal of Cancer Research and Clinical Oncology, 1990, 116, 207-214.	1.2	40
364	A case-control study of prostatic cancer in Kyoto, Japan: Sexual risk factors. Prostate, 1990, 17, 269-279.	1.2	35
365	Tobacco smoking, alcohol consumption, and risk of oral cancer: a case-control study in Beijing, People's Republic of China. Cancer Causes and Control, 1990, 1, 173-179.	0.8	88
366	Changing mortality from esophageal cancer in males in Denmark and other European countries, in relation to changing levels of alcohol consumption. Cancer Causes and Control, 1990, 1, 181-188.	0.8	12
367	Dentition, oral hygiene, and risk of oral cancer: a case-control study in Beijing, People's Republic of China. Cancer Causes and Control, 1990, 1, 235-241.	0.8	181
368	Extremely low-frequency electric and magnetic fields and risk of human cancer. Bioelectromagnetics, 1990, 11, 91-99.	0.9	23
369	Height and cancer risk in a network of case-control studies from northern Italy. International Journal of Cancer, 1990, 45, 275-279.	2.3	48
370	Anthropometric variables and risk of breast cancer. International Journal of Cancer, 1990, 45, 397-402.	2.3	43
371	Alcohol, beer and cancer of the pancreas. International Journal of Cancer, 1990, 45, 842-846.	2.3	37
372	The consumption of tobacco, alcohol and the risk of adenocarcinoma in Barrett's oesophagus. International Journal of Cancer, 1990, 45, 852-854.	2.3	68
373	Cancer Mortality in Italy. Tumori, 1990, 76, 85-86.	0.6	16
374	Projections to the end of the Century of Mortality from Major Cancer Sites in Italy. Tumori, 1990, 76, 420-428.	0.6	15
375	Some Further Consideration on the Role of Oral Contraceptives in Breast Carcinogenesis. Tumori, 1990, 76, 220-224.	0.6	7
376	Is the Increased Incidence of Primary Malignant Brain Tumors in the Elderly Real?. Journal of the National Cancer Institute, 1990, 82, 1594-1596.	3.0	63
377	Salt preference and the risk of gastrointestinal cancers. Nutrition and Cancer, 1990, 14, 227-232.	0.9	17
378	Medical History, Diet and Pancreatic Cancer. Oncology, 1990, 47, 463-466.	0.9	108

#	Article	IF	CITATIONS
379	The Relationship Between Oral Contraceptive Use, Cancer and Vascular Disease. Drug Safety, 1990, 5, 436-446.	1.4	17
380	Breast cancer risk and history of selected medical conditions linked with female hormones. European Journal of Cancer & Clinical Oncology, 1990, 26, 781-785.	0.9	71
381	The burden of cancer in Europe. European Journal of Cancer & Clinical Oncology, 1990, 26, 1111-1113.	0.9	5
382	SEARCH programme of the international agency for research on cancer. European Journal of Cancer & Clinical Oncology, 1990, 26, 547-549.	0.9	16
383	Therapy for testicular cancer in Central and Eastern Europe. Lancet, The, 1990, 335, 1033.	6.3	16
384	Cigarette smoking and bladder cancer. European Journal of Cancer & Clinical Oncology, 1990, 26, 714-718.	0.9	49
385	RE: "STATISTICAL MODELLING OF LUNG CANCER AND LARYNGEAL CANCER INCIDENCE IN SCOTLAND, 1960–1979― American Journal of Epidemiology, 1989, 129, 225-226.	1.6	4
386	Descriptive Epidemiology of Hodgkin's Disease in Italy. Tumori, 1989, 75, 401-405.	0.6	9
387	Reproductive factors and breast cancer: An overview. International Journal of Public Health, 1989, 34, 101-107.	2.7	25
388	Cancer incidence and mortality in Europe. International Journal of Public Health, 1989, 34, S3-S83.	2.7	206
389	Alcohol and breast cancer: Update from an Italian case-control study. European Journal of Cancer & Clinical Oncology, 1989, 25, 1711-1717.	0.9	37
390	Breast cancer and combined oral contraceptives: An Italian case-control study. European Journal of Cancer & Clinical Oncology, 1989, 25, 1613-1618.	0.9	16
391	Progress in understanding breast cancer: Epidemiological and biological interactions. Breast Cancer Research and Treatment, 1988, 11, 91-112.	1.1	42
392	Changes in testicular cancer in Scotland. European Journal of Cancer & Clinical Oncology, 1987, 23, 827-830.	0.9	77
393	Age, period and cohort models: The use of individual records. Statistics in Medicine, 1986, 5, 527-538.	0.8	81
394	International trends in prostatic cancer. International Journal of Cancer, 1984, 33, 223-230.	2.3	94